Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx Could Include 150 Part D Plans, CMS Official Estimates

Executive Summary

The Centers for Medicare & Medicaid Services anticipates that there will be up to 150 stand-alone Medicare Part D prescription drug plans in 2006, CMS Program Integrity Group Director Kimberly Brandt told the International Pharmaceutical Compliance Summit in Philadelphia April 1

You may also be interested in...



Medicare Rx Plans Have 15% Margin Of Error In Bids, Consultant Says

Medicare prescription drug plans will be able to remain profitable in the early years of the drug benefit even if their costs exceed the assumptions underlying their bid by as much as 15%, according to an analysis performed by the Gorman Health Group

Medicare Rx Plans Have 15% Margin Of Error In Bids, Consultant Says

Medicare prescription drug plans will be able to remain profitable in the early years of the drug benefit even if their costs exceed the assumptions underlying their bid by as much as 15%, according to an analysis performed by the Gorman Health Group

CMS Holds 300 Validated Formularies Prior To Delayed Submission Deadline

The Centers for Medicare & Medicaid Services has received and validated at least 300 drug formularies from potential Part D plan sponsors

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045649

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel